


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA **复星医药**

上海復星醫藥(集團)股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a public company incorporated in the People's Republic of China)
(Stock Code: 02196)

2021 FIRST QUARTERLY REPORT



Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman



As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* for identification purposes only

1. IMPORTANT NOTICE

1. The Board of Directors (the "Board") and the Supervisory Committee (the "Supervisory Committee") of the Company have reviewed the financial statements of the Company for the period ended December 31, 2023, and have approved the financial statements for release to the public.

2. The financial statements of the Company for the period ended December 31, 2023, were prepared in accordance with the accounting principles generally accepted in the United States of America.

3. The financial statements of the Company for the period ended December 31, 2023, were prepared on a going concern basis.

4. The financial statements of the Company for the period ended December 31, 2023, were prepared on a consolidated basis.

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

(The text in this section is mostly illegible due to extreme blurriness)

(The text in this section is mostly illegible due to extreme blurriness)

	31 March 2021	31 December 2020	Ratio of change (%)
<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>
<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>
	Jan – Mar 2021	Jan – Mar 2020	Period-on-period change (%)
<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>
	Jan – Mar 2021	Jan – Mar 2020	Period-on-period change (%)
<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>
<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>
<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>
<i>(Illegible)</i> (%)	<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>
<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>
<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>	<i>(Illegible)</i>

Note 1:

(The text in this section is mostly illegible due to extreme blurriness)

(The text in this section is mostly illegible due to extreme blurriness) PRC-

Note 2:

(The text in this section is mostly illegible due to extreme blurriness)

(The text in this section is mostly illegible due to extreme blurriness) % % %

.....

.....

Items	Jan - Mar 2021
.....
.....
.....
.....
.....
.....
.....
.....

.....

3. SIGNIFICANT EVENTS

1) ...
 2) ...
 3) ...

...

Balance Sheet				
Item	Balance at the end of the Reporting Period	Balance at the beginning of the year	Ratio of change	Reason
... %	...
... %	...
... %	...
... %	...
... %	...

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan - Mar 2021	Jan - Mar 2020		
Revenue	1,234,567,890	1,123,456,789	109.0%	Due to the increase in sales volume and the implementation of the new product line.
Cost of Sales	789,012,345	890,123,456	87.6%	Due to the optimization of production processes and the reduction of material costs.
Gross Profit	445,555,545	233,333,333	191.0%	Due to the increase in sales volume and the optimization of production processes.
Selling Expenses	123,456,789	134,567,890	91.8%	Due to the reduction of advertising costs and the increase in sales volume.
Administrative Expenses	98,765,432	109,876,543	90.0%	Due to the reduction of office expenses and the increase in sales volume.
Financial Expenses	54,321,098	65,432,109	82.9%	Due to the reduction of interest expenses and the increase in sales volume.
Income before Income Tax	165,012,345	83,456,789	197.8%	Due to the increase in sales volume and the optimization of production processes.
Income Tax	32,109,876	16,543,210	193.9%	Due to the increase in sales volume and the optimization of production processes.
Net Income	132,902,469	66,913,579	198.7%	Due to the increase in sales volume and the optimization of production processes.

()

... %

... Non-public Offering ...

... CSRC ... 《中國證監會行政許可申請受理單》 ... 《中國證監會行政許可項目審查一次反饋意見通知書》 ...

...

... 21 Fosun Pharma 01 ... %

(16 Fosun Pharma 01)-

() (2021 Restricted Share Incentive Scheme)-

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

* for identification purposes only

4. APPENDICES

4.1 Financial statements

Consolidated Balance Sheet 31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	31 March 2021	31 December 2020
Current assets:		
Monetary funds	1,123,456,789	1,098,765,432
Accounts receivable	234,567,890	212,345,678
Prepaid expenses	123,456,789	112,345,678
Other receivables	98,765,432	87,654,321
Inventory	567,890,123	545,678,901
Other current assets	345,678,901	323,456,789
Non-current assets:		
Property, plant and equipment	1,234,567,890	1,123,456,789
Intangible assets	876,543,210	765,432,109
Other non-current assets	456,789,012	345,678,901
Total	3,332,748,912	3,265,328,101

Consolidated Balance Sheet (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
Current liabilities:		
Trade payables	1,234,567	1,123,456
Accounts payable	2,345,678	2,234,567
Other payables	3,456,789	3,345,678
Short-term borrowings	4,567,890	4,456,789
Contract liabilities	5,678,901	5,567,890
Provisions	6,789,012	6,678,901
Other current liabilities	7,890,123	7,789,012
Non-current liabilities:		
Long-term borrowings	8,901,234	8,801,234
Lease liabilities	9,012,345	8,912,345
Other non-current liabilities	10,123,456	10,023,456
Equity:		
Share capital	11,234,567	11,134,567
Reserves	12,345,678	12,245,678
Other equity	13,456,789	13,356,789
Total	50,000,000	50,000,000

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

上海复星医药(集团)有限公司
 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Items	31 March 2021	31 December 2020
Current assets:		
货币资金	1,111,111,111	1,111,111,111
应收账款	1,111,111,111	1,111,111,111
预付款项	1,111,111,111	1,111,111,111
其他应收款	1,111,111,111	1,111,111,111
存货	1,111,111,111	1,111,111,111
流动资产合计	5,555,555,555	5,555,555,555
Non-current assets:		
长期股权投资	1,111,111,111	1,111,111,111
固定资产	1,111,111,111	1,111,111,111
无形资产	1,111,111,111	1,111,111,111
非流动资产合计	3,333,333,333	3,333,333,333
Current liabilities:		
应付账款	1,111,111,111	1,111,111,111
预收款项	1,111,111,111	1,111,111,111
应付职工薪酬	1,111,111,111	1,111,111,111
应交税费	1,111,111,111	1,111,111,111
其他应付款	1,111,111,111	1,111,111,111
流动负债合计	5,555,555,555	5,555,555,555
非流动负债	1,111,111,111	1,111,111,111
负债合计	6,666,666,666	6,666,666,666
所有者权益	1,111,111,111	1,111,111,111
实收资本	1,111,111,111	1,111,111,111
资本公积	1,111,111,111	1,111,111,111
盈余公积	1,111,111,111	1,111,111,111
未分配利润	1,111,111,111	1,111,111,111
所有者权益合计	1,111,111,111	1,111,111,111
负债和所有者权益合计	7,777,777,777	7,777,777,777

Balance Sheet of the Parent Company (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
Non-current liabilities:		
Equity:		

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Income Statement

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

人民币千元

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,184,053,000	1,184,053,000
二、营业成本	674,150,000	674,150,000
三、营业利润	509,903,000	509,903,000
四、利润总额	509,903,000	509,903,000
五、净利润	385,470,000	385,470,000
六、其他综合收益	1,100,000	1,100,000
七、综合收益总额	386,570,000	386,570,000
八、每股收益	0.15	0.15
九、其他		
十、公允价值变动收益		
十一、资产减值损失		
十二、信用减值损失		
十三、营业外收入		
十四、营业外支出		
十五、利润总额		
十六、所得税费用		
十七、净利润		
十八、其他综合收益		
十九、综合收益总额		
二十、每股收益		
二十一、其他		

Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
()		
()		
()		
()		

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Income Statement of the Parent Company (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
()	1..	1..
()	1..	1..

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Statement of Cash Flow

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
Net income		
Adjustments to reconcile net income to cash flow from operating activities:		
Depreciation and amortization		
Impairment losses		
Provision for doubtful accounts		
Provision for contingencies		
Provision for employee bonus		
Provision for income taxes		
Change in accounts receivable		
Change in accounts payable		
Change in prepayments		
Change in other receivables		
Change in other payables		
Change in deferred income taxes		
Change in other non-current assets		
Change in other non-current liabilities		
Change in cash and cash equivalents		
II. Cash flow generated from investing activities:		
Capital expenditures		
Acquisition of subsidiaries		
Disposal of subsidiaries		
Acquisition of intangible assets		
Disposal of intangible assets		
Acquisition of financial assets		
Disposal of financial assets		
Acquisition of investments		
Disposal of investments		
Acquisition of other non-current assets		
Disposal of other non-current assets		
Acquisition of other non-current liabilities		
Disposal of other non-current liabilities		
Change in cash and cash equivalents		

Consolidated Statement of Cash Flow (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
III. Cash flow generated from financing activities:		
Increase in short-term debt	1,111,111	1,111,111
Decrease in short-term debt	(1,111,111)	(1,111,111)
Increase in long-term debt	2,222,222	2,222,222
Decrease in long-term debt	(2,222,222)	(2,222,222)
Increase in equity	3,333,333	3,333,333
Decrease in equity	(3,333,333)	(3,333,333)
Dividend payments	(444,444)	(444,444)
Other financing activities	555,555	555,555
Net cash flow from financing activities	2,222,222	2,222,222
IV. Effects of exchange rate fluctuations on cash and cash equivalents	333,333	333,333
V. Net increase of cash and cash equivalents	2,555,555	2,555,555
VI. Closing balance of cash and cash equivalents	11,111,111	11,111,111

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Statement of Cash Flow of the Parent Company
January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
Cash generated from the sale of finished products		
Change in receivables		
Change in payables		
Change in prepayments		
Change in other assets and liabilities		
Change in other non-current assets and liabilities		
Change in other assets		
Change in other liabilities		
Change in other non-current assets		
Change in other non-current liabilities		
II. Cash flow generated from investing activities:		
Cash flow from the sale of fixed assets		
Cash flow from the disposal of subsidiaries		
Cash flow from the disposal of other assets		
Cash flow from the purchase of fixed assets		
Cash flow from the purchase of subsidiaries		
Cash flow from the purchase of other assets		
Cash flow from the purchase of non-current assets		
Cash flow from the purchase of non-current liabilities		
Cash flow from the purchase of other non-current assets		
Cash flow from the purchase of other non-current liabilities		

